Table 1 Clinical baseline characteristics of 667 patients hospitalized with symptomatic heart failure according to HFE genotype
From: Hereditary Hemochromatosis (HFE) genotypes in heart failure: Relation to etiology and prognosis
HFE variant | C282Y | H63D | S65C | Any variation | ||||
|---|---|---|---|---|---|---|---|---|
Status | Carrier | non-carrier | Carrier | non-carrier | Carrier | non-carrier | Carrier | Non-carrier |
n total | 73 | 594 | 144 | 523 | 26 | 641 | 231 | 436 |
Clinical data | ||||||||
Age (years) | 72.0 (43.6-86.8) | 71.1 (49.5-85.9) | 71.3 (46.5-87.8) | 71.1 (49.5-85.3) | 72.6 (46.0-80.6) | 71.1 (48.4-86.0) | 71.5 (46.0-87.1) | 71.0 (50.0-85.9) |
male | 55 (75) | 430 (72) | 106 (74) | 379 (72) | 18 (69) | 467 (73) | 170 (74) | 315 (72) |
BMI (kg/m2) | 26.4 (20.3-35.1) | 26.0 (18.8-35.3) | 26.4 (18.7-34.4) | 25.9 (19.2-35.3) | 26.0 (16.7-44.7) | 26.0 (19.1-35.1) | 26.3 (19.2-35.1) | 25.8 (19.1-35.3) |
Current smoker (%) | 21 (29) | 191 (33) | 41 (29) | 171 (33) | 11 (44) | 201 (32) | 69 (30) | 143 (33) |
NYHA classes (%) | ||||||||
NYHA class I | 1 (1) | 21 (3) | 7 (5) | 10 (2) | 0 | 17 (3) | 8 (3) | 9 (2) |
NYHA class II | 12 (16) | 181 (28) | 42 (29) | 122 (23) | 6 (23) | 158 (25) | 58 (25) | 106 (24) |
NYHA class III | 47 (64) | 360 (56) | 76 (53) | 315 (61) | 15 (58) | 376 (59) | 132 (57) | 259 (60) |
NYHA class IV | 13 (18) | 80 (12) | 19 (13) | 73 (14) | 5 (19) | 87 (14) | 33 (14) | 59 (14) |
Medical history | ||||||||
CHF (%) | 62 (86) | 502 (85) | 115 (80) | 449 (86) | 23 (86) | 541 (85) | 189 (83) | 375 (86) |
IHD (%) | 30 (41)* | 317 (53) | 65 (45) | 282 (54) | 14 (54) | 333 (52) | 104 (45)¤ | 243 (56) |
Former AMI (%) | 23 (32) | 217 (37) | 51 (35) | 189 (36) | 9 (36) | 231 (36) | 78 (34) | 162 (37) |
Hypertension (%) | 24 (33) | 139 (23) | 36 (25) | 127 (24) | 9 (35) | 154 (24) | 66 (29) | 97 (22) |
COPD (%) | 14 (19) | 127 (21) | 31 (22) | 110 (21) | 8 (31) | 133 (21) | 52 (23) | 89 (20) |
Diabetes diagnosis (%) | 13 (18) | 102 (17) | 25 (17) | 90 (17) | 7 (27) | 108 (17) | 42 (18) | 73 (17) |
Hyperlipidaemia (%) | 22 (32) | 217 (37) | 50 (35) | 189 (37) | 9 (36) | 230 (37) | 76 (34) | 163 (38) |
Stroke/TCI (%) | 14 (19) | 70 (12) | 16 (11) | 68 (13) | 6 (23) | 78 (12) | 34 (15) | 50 (11) |
Medication at discharge | ||||||||
ACE-I (%) | 52 (72) | 474 (80) | 115 (80) | 411 (79) | 20 (77) | 506 (79) | 178 (77) | 348 (80) |
AT-II blockers (%) | 7 (10) | 53 (9) | 13 (9) | 47 (9) | 4 (15) | 56 (9) | 24 (10) | 36 (8) |
β-Blokage (%) | 43 (60) | 298 (50) | 70 (49) | 271 (52) | 14 (54) | 327 (51) | 121 (53) | 220 (51) |
Diuretics (%) | 71 (99) | 578 (98) | 142 (99) | 507 (98) | 25 (96) | 624 (98) | 226 (98) | 423 (98) |
Paraclinical data | ||||||||
WMI | 1.0 (0.4-1.2) | 0.9 (0.5-1.2) | 0.9 (0.5-1.2) | 0.9 (0.4-1.2) | 0.9 (0.4-1.2) | 0.9 (0.5-1.2) | 0.9 (0.4-1.2) | 0.9 (0.5-1.2) |
Serum Ferritin (ng/ml) | 121 (31-582) | 123 (35-430) | 129 (29-430) | 122 (36-443) | 159 (42-260) | 121 (35-461) | 127 (29-417) | 121 (37-466) |
Hemoglobin (mmol/l) | 8.8 (7.1-10.8) | 8.6 (6.7-10.4) | 8.7 (7.0-10.4)† | 8.6 (6.7-10.4) | 8.4 (6.9-9.6) | 8.6 (6.8-10.4) | 8.7 (7.0-10.4)¶ | 8.5 (6.6-10.4) |
Serum creatinin (μmol/l) | 99 (68-259) | 106 (68-203) | 108 (70-201) | 104 (67-208) | 120 (73-251)‡ | 105 (68-198) | 108 (68-222) | 103 (67-194) |
BNP (pmol/L) | 1.5 (0.3-4.0) | 1.3 (0.4-4.1) | 1.3 (0.3- 3.7) | 1.4 (0.4- 4.1) | 1.3 (0.2- 4.7) | 1.3 (0.4-4.0) | 1.3 (0.3-4.2) | 1.3 (0.4-4.0) |